Release Date: April 19, 2022
Expiration Date: April 19, 2023
Activity Overview
Type 2 diabetes (T2D) is a leading cause of morbidity and mortality worldwide, and it is estimated that 9.3% of the global population is affected by this condition. Diabetic kidney disease (DKD) is a disease multiplier that increases the risk of stroke, cardiac and vascular disease. It affects up to 40% of patients with diabetes during their lifespan, exposing them to a 3-fold higher risk of cardiovascular (CV) death compared with those with diabetes alone. In fact, patients with DKD are far more likely to die from cardiovascular disease (CVD) than to progress to end-stage renal disease (ESRD). Not surprisingly, this burden of complications and comorbidity translates to poor quality of life (QoL) and substantially higher health care resource utilization and costs.
During this Clinical Consultations™ program, 2 expert faculty discuss the importance of screening patients with chronic kidney disease (CKD) for comorbidities and treating them early. They also discuss the treatment options available among both current and emerging classes of therapies and across different clinical subspecialties.
Target Audience
This educational activity is directed toward nephrologists, cardiologists, primary care providers, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with CKD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize current guideline recommendations regarding testing for CKD in at-risk patients with T2D
- Discuss clinical trial evidence regarding therapies for patients with CKD and CV comorbidities
- Develop treatment plans for patients with CKD and CV comorbidities based on current evidence and patient presentation
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here